Funding for this research was provided by:
Centers for Disease Control and Prevention (U48DP005013.)
National Cancer Institute (R01CA121125)
National Institutes of Health (U54 AT007748)
Received: 11 October 2018
Accepted: 13 May 2019
First Online: 29 May 2019
Ethics approval and consent to participate
: The study was approved by the Institutional Review Board of University of Washington (STUDY00000472).
: Not applicable, no consent was required.
: This manuscript was supported by grants from the following:UnorderedList removedThe views presented here are solely the responsibility of the authors and do not necessarily represent the official views of the NCI, NIH, or CDC.From November 2014 to August 2015, Dr. Coronado served as a co-Investigator on an industry-funded study to evaluate patient adherence to an experimental blood test for colorectal cancer. The study was funded by EpiGenomics. From September 2017 to June 2018, Dr. Coronado served as the Principal Investigator on an industry-funded study to compare the clinical performance of an experimental FIT to an FDA-approved FIT. This study was funded by the Quidel Corporation. All other authors declare no conflicts of interest.The other authors report no conflicts of interest other than the funding that was awarded to their institutions for these grants. All authors take responsibility for the design, writing, editing, and final version submitted.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.